Effect of fructose on postprandial triglycerides: A systematic review and meta-analysis of controlled feeding trials  by David Wang, D. et al.
lable at ScienceDirect
Atherosclerosis 232 (2014) 125e133Contents lists avaiAtherosclerosis
journal homepage: www.elsevier .com/locate/atherosclerosisReviewEffect of fructose on postprandial triglycerides: A systematic review
and meta-analysis of controlled feeding trials
D. David Wang a,b, John L. Sievenpiper b,c,*, Russell J. de Souza b,d, Adrian I. Cozma a,b,
Laura Chiavaroli a,b, Vanessa Ha a,b, Arash Mirrahimi b,e, Amanda J. Carleton b,f,
Marco Di Buono a, Alexandra L. Jenkins b, Lawrence A. Leiter a,b,g,h,i,
Thomas M.S. Wolever a,b,g,h, i, Joseph Beyene d,j,k, Cyril W.C. Kendall a,d, l,
David J.A. Jenkins a,b,g,h, i
aDepartment of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
b Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modiﬁcation Centre, Toronto, ON, Canada
cDepartment of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
dDepartment Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
e School of Medicine, Faculty of Medicine, Queen’s University, Kingston, ON, CANADA
fUndergraduate Medical Education (MD Program), Faculty of Medicine, University of Toronto, Toronto, ON, Canada
gKeenan Research Center of the Li Ka Shing Knowledge Institute, Toronto, ON, Canada
hDivision of Endocrinology, St. Michael’s Hospital, Toronto, ON, Canada
iDepartment of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
jDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
k Population Health Sciences, Research Institute Hospital for Sick Children, Toronto, ON, Canada
lCollege of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canadaa r t i c l e i n f o
Article history:
Received 23 May 2013
Received in revised form
9 October 2013
Accepted 22 October 2013




Lipids and lipoprotein metabolism
Clinical trial
Systematic review
Meta-analysis* Corresponding author. Toronto 3D Knowledge Syn
Queen Street East, Toronto, ON M5C 2T2, Canada. Tel
E-mail addresses: john.sievenpiper@utoronto.ca, jo
0021-9150  2013 The Authors. Published by Elsevie
http://dx.doi.org/10.1016/j.atherosclerosis.2013.10.019a b s t r a c t
Background: In the absence of consistent clinical evidence, concerns have been raised that fructose raises
postprandial triglycerides.
Purpose: A systematic review and meta-analysis was conducted to assess the effect of fructose on
postprandial triglycerides.
Data sources: Relevant studies were identiﬁed from MEDLINE, EMBASE, and Cochrane databases
(through September 3, 2013).
Data selection: Relevant clinical trials of 7-days were included in the analysis.
Data extraction: Two independent reviewers extracted relevant data with disagreements reconciled by
consensus. TheHeylandMethodologicalQualityScore (MQS) assessed studyquality.Datawerepooledby the
generic inverse variance method using random effects models and expressed as standardized mean differ-
ences (SMD) with 95% conﬁdence intervals (CI). Heterogeneity was assessed (Cochran Q statistic) and
quantiﬁed (I2 statistic).
Data synthesis: Eligibility criteria were met by 14 isocaloric trials (n ¼ 290), in which fructose was
exchanged isocalorically for other carbohydrate in the diet, and two hypercaloric trials (n ¼ 33), in which
fructose supplemented the background diet with excess energy from high-dose fructose compared with
the background diet alone (without the excess energy). There was no signiﬁcant effect in the isocaloric
trials (SMD: 0.14 [95% CI: 0.02, 0.30]) with evidence of considerable heterogeneity explained by a single
trial. Hypercaloric trials, however, showed a signiﬁcant postprandial triglyceride raising-effect of fructose
(SMD: 0.65 [95% CI: 0.30, 1.01]).
Limitations: Most of the available trials were small, short, and of poor quality. Interpretation of the
isocaloric trials is complicated by the large inﬂuence of a single trial.thesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modiﬁcation Centre, St. Michael’s Hospital, #6137-61
.: þ1 416 867 7475; fax: þ1 416 867 7495.
hn.sievenpiper@medportal.ca (J.L. Sievenpiper).
r Ireland Ltd. Open access under CC BY-NC-SA license.
D. David Wang et al. / Atherosclerosis 232 (2014) 125e133126Conclusions: Pooled analyses show that fructose in isocaloric exchange for other carbohydrate does not
increase postprandial triglycerides, although an effect cannot be excluded under all conditions. Fructose
providing excess energy does increase postprandial triglycerides. Larger, longer, and higher-quality trials
are needed.
Protocol registration: ClinicalTrials.gov identiﬁer, NCT01363791.
 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-SA license.Contents
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Postprandial lipids were ﬁrst associated with atherogenesis in
1979 by Zilversmit [1]. Several studies have demonstrated that non-
fasting trigycerides, in particular peak postprandial triglycerides,
are better predictors of cardiovascular risk than fasting tri-
glycerides. The Copenhagen City Heart Study demonstrated an as-
sociation between increased nonfasting triglycerides and
myocardial infarction and death with postprandial triglycerides 4 h
after the last meal (within the peak range) the strongest predictors
of cardiovascular events [2]. In the Women’s Health Study, non-
fasting triglyceride levels were more strongly correlated with car-
diovascular disease incidence than fasting triglycerides, which lost
signiﬁcance after adjustment for total and HDL cholesterol [3].
Based on these data, the American Heart Association has proposed
an initial lipid screen for non-fasting triglycerides with a cut point
of 200 mg/dL (2.26 mM) [4].
Dietary factors which contribute to raised postprandial tri-
glycerides have become a focus of concern. Particular attention has
been focussed on the role of fructose. Highly reproducible animal
models of fructose overfeeding have shown raised triglycerides
secondary to increases in triglyceride secretion [5], impaired VLDL
clearance, and enhanced fatty acid esteriﬁcation [6]. Whether these
ﬁndings hold true in humans under “real-world” intake patterns is
unclear. Earlier systematic reviews and meta-analyses of controlled
feeding trials have suggested a dose threshold for triglyceride-raising effects of fructose with increases in fasting triglyceride
seen only at doses>60-g/day in type 2 diabetes [7] and100-g/day
across differentmetabolic phenotypes [8]. The threshold appears to
be even lower for postprandial triglycerides with increases seen
only at 50-g/d [8], a threshold roughly equivalent to the average
fructose intake in the US [9]. This effect of fructose on postprandial
triglycerides, however, is derived largely from acute, single-bolus
studies [8]. The effect of fructose on postprandial triglycerides
under chronic feeding conditions needs further investigation.
To assess the effects of longer-term fructose intake on post-
prandial triglycerides, we conducted a systematic review andmeta-
analysis of controlled feeding trials.
2. Methods
We followed the Cochrane Handbook for Systematic Reviews of
Interventions for the planning and conduct of this meta-analysis
[10]. The reporting followed the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) guidelines [11].
The review protocol is available at ClinicalTrials.gov (registration
number: NCT01363791).
2.1. Study selection
We searched Ovid MEDLINE (1946 through September 3, 2013),
Embase (1980 through September 3, 2013) and The Cochrane
D. David Wang et al. / Atherosclerosis 232 (2014) 125e133 127Library (1991 through September 3, 2013), using the search terms:
“fructose AND (triglyceride OR triacylglycerol OR triacylglyceride
OR VLDL OR LDL OR chylomicron OR lipemia OR lipaemia OR lipid
OR apoB100 OR apoB48 OR cholesterol)”. No restrictions were
placed on language or study type during the search. We included
clinical interventions that investigated the chronic effect of
exchanging isocaloric or hypercaloric oral fructose for a reference
carbohydrate on postprandial triglycerides in humans. Compari-
sons were considered “isocaloric” if oral fructose in the fructose
arm was exchanged for the reference carbohydrate in the control
arm in an iso-energetic and iso-glucidic manner and “hypercaloric”
if the oral fructose in the fructose arm was provided as a supple-
ment to the background diet providing excess energy (E) relative to
the background diet alone in the control arm. Trials with <7 days
follow-up, which lacked an adequate carbohydrate control, or
administered IV-fructose were excluded.
2.2. Data extraction
Two reviewers (DW and AC) independently extracted the
following study characteristics: design (parallel or crossover),
randomization, blinding, sample size, subject characteristics (age,
sex, BMI, and diabetes status), fructose form (solid, liquid or mixed),
dose, control reference carbohydrates (sucrose, starch, glucose,
high-fructose corn syrup), follow-up, and macronutrient proﬁle of
the background diet. The quality of each studywas assessed by each
reviewer using the Heyland Methodological Quality Score (MQS)
which assigns a score from 0 to 1 or 0e2 over 9 categories of quality
related tostudydesign, samplingprocedures, and interventions for a
total of 13 points [12]. Trials receiving scores of 8 or more wereFig. 1. Flow of the literature search. “unsuitable endpoints” indconsidered to be of higher quality. Disagreements were reconciled
by consensus through discussion with another investigator (JLS).
Mean  SD postprandial triglyceride endpoints (peak or mean
postprandial triglycerides, 24 h post-meal area under the curve for
triglycerides, and 2-h triglyceride difference post-meal) were
extracted. For trials reporting post-meal area under the curve, peak
postprandial triglycerides values were extracted from the graph.
Trials reporting both start and end values had change from baseline
values calculated. End differenceswere calculated for all other trials.
Missing SD values were calculated from SEM, P-values, or t statistics
using standard formulas [13]. Where these statistics were not re-
ported, SD values were imputed using a correlation coefﬁcient,
derived from a trial reporting complete data, for between treatment
SD [13]. If SD coefﬁcients could not be imputed, then missing SDs
were derived from the pooled-SD imputed for the other trials [14].
2.3. Statistical analyses
Data were analyzed using Review Manager (RevMan) version
5.1.6 (The Nordic Cochrane Centre, The Cochrane Collaboration,
Copenhagen, Denmark) for primary analyses and Stata (version 12,
College Station, USA) for subgroup and dose response analyses.
Pooled analyses for isocaloric fructose feeding trials were con-
ducted using the Generic Inverse Variance method using random
effects models. Analyses were stratiﬁed by diabetes and non-
diabetes. The main outcome was postprandial triglycerides re-
ported as peak, mean, or 2-h change from baseline. Where more
than one of these endpoints was reported, the order of preference
was peak > mean > 2-h change from baseline postprandial tri-
glycerides. Owing to the pooling of different postprandialicates the absence of postprandial triglycerides endpoints.
Table 1
Characteristics of controlled feeding trials investigating the effect of fructose on postprandial triglycerides.a









Bantle et al., 1986 [23] 12 DM1 (6-M: 6-F) 23-y (15e32-y) 1.54  0.78-mM O P, USA C M Yes
Bantle et al., 1986 [23] 12 DM2 (5-M: 7-F) 62-y (36e80-y) 3.27  0.79-mM OP, USA C M Yes
Anderson et al., 1989 [26] 14 DM2 (14-M:0-F) 60  15-y 2.69  0.40-mM IP/OP, USA C S No
Bantle et al., 1992 [17] 6 DM1 (3-M: 3-F) 23-y (18e34-y) 1.05  0.61-mM OP, USA C M Yes
Bantle et al., 1992 [17] 12 DM2 (4-M: 8-F) 62-y (40e72-y) 2.34  0.87-mM OP, USA C M Yes
Malerbi et al., 1996 [18] 16 DM2 (7-M:9-F) 54-y (34e66-y) 2.25  0.40-mM OP, Brazil C S No
Vaisman et al., 2006 [22] 25 DM2 62  10-y Starch: 0.40  0.34-mM
Fructose: 0.16  0.53-mM
O P, Isreal P S Yes
Overweight/obesity
Swarbrick et al., 2008 [21] 7 OW/OB (0-M:7-F) 61-y (50e72-y) 1.07  0.92-mM IP, USA C M No
Stanhope et al., 2009 [25] k 32 OW/OB
(16-M:16-F)
54  8.1-y Glucose: 2.57  0.90-mM
Fructose: 3.19  0.96-mM
IP/OP, USA P M/S No
Otherwise healthy
Huttenen et al., 1976 [24] 68 N 28  7.0-y Sucrose: 1.57  0.92-mM
Fructose: 1.46  0.65-mM
OP, Finland P S No
Swanson et al., 1992 [20] 14 N (7-M:7-F) 34-y (19e60-y) 1.28  0.60-mM OP, Denmark C M Yes
Bantle et al., 2000 [16] 12 N (12-M) 42  12-y 1.33  0.79-mM OP, USA C M Yes
Bantle et al., 2000 [16] 12 N (12-F) 40  11-y 1.88  0.79-mM OP, USA C M Yes
Stanhope et al., 2011 [19] k 48 N (27-M:21-F) 28  7.1-y Glucose: 1.5  0.8-mM
HFCS: 1.8  0.8-mM
IP/OP, USA P M/S No
Hypercaloric trials
Overweight/obesity
Stanhope et al., 2009 [25] k 17 OW/OB (9-M:8-F) 52  9.3-y 2.39  1.32-mM IP/OP, USA C M/S No
Otherwise healthy
Stanhope et al., 2011 [19] k 16 N (9-M:7-F) 28  6.8-y 1.20  0.40-mM IP/OP, USA C M/S No
a DM1 denotes type 1 diabetesmellitus; M, male(s); F, female(s); DM2, type 2 diabetes mellitus; OW, overweight; OB, obese; N, normal, y, year; P, parallel; C, crossover; IP,
inpatient; OP, outpatient; M, metabolic; S, supplement; E, energy; wk, week(s); d, days; h, hours; PPTG, postprandial triglycerides.
b Baseline postprandial triglycerides represents baseline postprandial triglycerides or the postprandial triglycerides on the control treatment (comparator) in the
crossover trials. It represents the baseline postprandial triglycerides on each treatment arm in the parallel trials.
c Designs were either crossover (C) or parallel (P).
d Metabolic (M) feeding control represents the provision of all meals, snacks, and study supplements (test sugars and foods) consumed during the study under controlled
conditions. Supplement (S) feeding control represents the provision of study supplements.
e Doses were administered on a g/d, % energy, or g/kg bodyweight basis. Doses preceded by “w” represent average doses calculated based on the average reported energy
intake or weight of participants. If these data were not available, then the average dose was based on a 2000-kcal intake or 70-kg weight.
f Fructose was provided in one of three forms: (1) liquid form, where all or most of the fructose was provided as beverages or crystalline fructose to be added to beverages;
or (2) mixed form, where all or most of the fructose was provided as a mix of beverages, solid foods (not fruit), and/or crystalline fructose.
g Comparator refers to the reference carbohydrate (starch, glucose, sucrose, or HFCS) in the isocaloric trials and diet alone (weight-maintaining, background diet) in the
hypercaloric trials. Fructose was exchanged for the reference carbohydrate providing an energy matched comparison in the “isocaloric” trials, whereas it was added to the
diet alone (+fructose) providing excess energy relative to the diet alone in the hypercaloric trials.
h Values are for energy from carbohydrate:fat:protein. “e” indicates that the information was not available.
i Study quality was assessed by the Heyland Methodological Quality Score (MQS) (12). Trials scored 8 were considered to be of higher quality.
j Agency funding represents funding from government, university, or not-for-proﬁt, health agency sources. None of the trialists declared any conﬂicts of interest.
k Two reports (19,25) contained both isocaloric and hypercaloric trials. In the isocaloric trials, there was over-feeding (positive energy balance) on both the fructose and
comparator arms, such that the comparisons were energy matched. The fructose and comparator (glucose) arms in the two isocaloric, parallel trials also featured an
outpatient ad libitum, over-feeding period (8-weeks and 10-days, respectively) followed by a shorter inpatient energy-balanced, weight-maintaining period (2-weeks and
3.5-days, respectively). The same fructose arm was compared with the diet alone given over a shorter inpatient energy-balanced, weight-maintaining period (2-weeks and
3.5-days, respectively) in the hypercaloric, crossover trials. The MQSwas higher for the isocaloric, parallel trials than the hypercaloric, crossover trials of Stanhope et al. (25),
as the hypercaloric trials were not blinded and randomized, respectively.
D. David Wang et al. / Atherosclerosis 232 (2014) 125e133128triglyceride endpoints, data were expressed as standardized mean
differences (SMD) with 95% CI, where SMD is interpreted as fol-
lows: <0.4 is small effect size, 0.4e0.7 is a moderate effect size, and
>0.7 is a large effect size. Change from baseline differences were
preferred to end differences. Paired analyses were applied to all
crossover trials according to Elbourne et al. [14]. To prevent a unit-
of-analysis error induced by including trials with multiple inter-
vention arms, we combined arms to create single pair-wise com-
parisons. Inter-study heterogeneity was tested by Cochran’s Q (c2)
with the signiﬁcance level set at P < 0.10 and quantiﬁed by the I2
statistic, where I2  50% is evidence of substantial heterogeneity
and 75%, considerable heterogeneity [10]. Potential sources of
methodological heterogeneity were investigated by sensitivity an-
alyses and a priori subgroup analyses, investigating the effect of
comparator (starch, sucrose, glucose or HFCS), fructose format
(ﬂuid or mixed), dose (Canadian Diabetes Association (CDA)
thresholds [15], 60-g/day or >60-g/day) follow-up (4-weeksor >4-weeks), randomization, study design (parallel or cross-
over), study quality (MQS < 8 or 8), and energy balance (neutral,
positive). A continuous dose response relationship was assessed by
random effects meta-regression.
2.4. Role of the funding source
This work was funded by a Canadian Institutes of Health
Research (CIHR) Knowledge Synthesis grant (funding reference
number, 102078) and a grant from the Calorie Control Council. R.J.D.
was funded by a CIHR Postdoctoral Fellowship Award, A.M. was
funded by a CIHR Canada Graduate Scholarship Master’s award and
DJAJ was funded by the Government of Canada through the Canada
Research Chair Endowment. None of the sponsors had a role in any
aspect of the present study, including design and conduct of the
study; collection, management, analysis, and interpretation of the
data; and preparation, review, or approval of the manuscript.
Fructose dosee Fructose
formf
Comparatorg Dieth Energy balance Follow-up MQSi Endpoint Funding typej
-
w136-g/d (21% E) Mixed Starch, Sucrose 55:30:15 Neutral 8-d 8 Peak-PPTG Agency-Industry
w136-g/d (21% E) Mixed Starch, Sucrose 55:30:15 Neutral 8-d 8 Peak-PPTG Agency-Industry
w55-g/d (12% E) Mixed Starch 55:25:20 Neutral 23-wk 8 Mean-PPTG Agency-Industry
w120-g/d (20% E) Mixed Starch 55:30:15 Neutral 4-wk 8 Peak-PPTG Agency-Industry
w120-g/d (20% E) Mixed Starch 55:30:15 Neutral 4-wk 8 Peak-PPTG Agency-Industry
63.2-g/d (20% E) Liquid Starch, Sucrose 55:30:15 Neutral 4-wk 7 Mean-PPTG Agency-Industry
22.5-g/d (4.5% E) Mixed Starch e Neutral 12-wk 5 2 h-PPTG e
w125-g/d (25% E) Liquid Starch 55:30:15 Neutral 10-wk 7 Peak-PPTG Agency
w182-g/d (+25% E) Liquid Glucose 55:30:15 Positive 2-wk 6 Peak-PPTG Agency
69 g/d (14% E) Mixed Sucrose e Neutral 95-wk 5 Peak-PPTG e
w120-g/d (20% E) Mixed Starch 55:15:30 Neutral 4-wk 8 Peak-PPTG Agency-Industry
85-g/d (17% E) Mixed Glucose 55:30:15 Neutral 6-wk 9 Peak-PPTG Agency
85-g/d (17% E) Mixed Glucose 55:30:15 Neutral 6-wk 9 Peak-PPTG Agency
w168-g/d(+25% E) Liquid Glucose, HFCS 55:30:15 Positive 2-wk 6 Peak-PPTG Agency
w+182-g/d (+25% E) Liquid Diet alone 55:30:15 Positive 8-wk 5 Peak-PPTG Agency
w+168-g/d(+25% E) Liquid Diet alone 55:30:15 Positive 2-wk 6 Peak-PPTG Agency
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3.1. Search results
Fig.1 shows the systematic searchandselectionof the literature.A
totalof 1259 reportswere identiﬁedaseligibleon the initial search, of
which 1211 reports were excluded based on the title or abstract. The
remaining 48 reports were retrieved and reviewed, where a further
37were excluded. A total of 11 reportsmet the eligibility criteria and
were included in this meta-analysis [16e26]. These 11 reports con-
tained 14 isocaloric trials and 2 hypercaloric trials.
3.2. Trial characteristics
Trial characteristics are shown in Table 1. There were 14 isoca-
loric trials in 290 otherwise healthy (5 trials), overweight/obese (2
trials), and diabetic participants and 2 hypercaloric trials involving
33 participants without diabetes. Participants in isocaloric trials
tended to be older (median age, 54 years [range, 23e62 years]) and
male (51%), whereas those in hypercaloric trials were middle-aged
(median age, 40 years [range, 28e52 years]) and similarly, male
(55%). Median baseline postprandial triglycerides was 1.61 mmol/L
([IQR: 1.28e2.34 mmol/L]) in isocaloric trials and 1.80 mmol/L
(range, 1.20e2.39 mmol/L) in the two hypercaloric trials.
Isocaloric and hypercaloric trials tended to be small (median
number of participants, 14 [range, 6e68] and 16.5 [range, 16e17],
respectively). Most (71%) isocaloric trials were conducted in outpa-
tient settings (71%) with the majority of trial centers located in the
United States (71%). Both hypercaloric trials were conducted in
outpatient/inpatient settings intheUnitedStates. Follow-upwasshort
with a median follow-up of 4 weeks (range, 2- to 95 weeks) in the
isocaloric trials and 5 weeks (range, 2e8 weeks) in the two hyper-
caloric trials.
Most isocaloric trials (57%) and neither of the hypercaloric trials
were randomized. Most isocaloric (71%) trials and both hyper-
caloric trials also used crossover designs. Comparators in isocalorictrials were starch (8 trials), sucrose (3 trials), glucose (4 trials)
and HFCS (1 trial); the background diet alone was the comparator
in both hypercaloric trials. Fructose was administered in mixed
(71%) form in the isocaloric trials and in ﬂuid form in both
hypercaloric trials. Median fructose doses were 120-g/d (range,
22.5e182 g/d) or 20% E (range, 4.5e25% E) in the isocaloric trials
and þ175-g/d (range, þ168e182 g/d) or þ25% E in the two
hypercaloric trials.
The diets provided a range of energy andmacronutrient proﬁles.
Most isocaloric trials (86%) provided energy under weight-
maintaining conditions (neutral energy balance), but 2 trials
(15%) provided excess energy in both trial groups (positive energy
balance) [19,25]. Macronutrients were similar across the isocaloric
and hypercaloric trials: 55% carbohydrate energy, 15e30% and 30%
fat energy, and 15e30% and 15% protein energy, respectively.
Metabolic feeding control was used by the majority of isocaloric
trials (46%), while a combination of metabolic and supplement
feeding control was used by both hypercaloric trials.
The Heyland MQS (maximum possible score, 13) ranged from 6
to 8 in isocaloric trials and from 5 to 6 in the two hypercaloric trials;
8 isocaloric trials (57%) and neither of the hypercaloric trials were
considered high quality (Heyland MQS  8). Research funding was
reported from agency (44%), a combination of agency and industry
(44%), or undeclared (12%) sources.
3.3. Isocaloric feeding trials
There was no signiﬁcant effect of isocaloric exchange of fructose
for other carbohydrate in the overall analysis (SMD : 0.14 [95%
CI: 0.02, 0.30]) (Fig. 2). There was, however, a signiﬁcant
triglyceride raising effect in overweight/obese participants
(SMD: 0.69 [95% CI: 0.20, 1.19]) and a tendency for a post-
prandialtriglyceride raising effect in otherwise healthy participants
(SMD ¼ 0.30 [95% CI: 0.00, 0.60], P ¼ 0.05). The effect in partici-
pants with diabetes was not signiﬁcant (SMD:0.00 [95% CI:0.15,
0.14]). There was also evidence of considerable interstudy
Fig. 2. Forest plots of controlled feeding trials of the effect of isocaloric exchange of fructose for other sources of carbohydrate on pooled postprandial triglyceride endpoints in
diabetic and non-diabetic subjects. Three pooled effect estimates (diamonds) are shown: one each for trials in diabetes, non-diabetes, and their combination. Paired analyses were
applied to all crossover trials. Data are standardized mean differences (SMD) with 95% CI. P values are for Generic Inverse Variance random effects models. Inter-study heterogeneity
was tested by Cochran’s Q at a signiﬁcance level of P < 0.10 and quantiﬁed by I2.
D. David Wang et al. / Atherosclerosis 232 (2014) 125e133130heterogeneity in the effect seen in otherwise healthy participants
(I2 ¼ 70%, P ¼ 0.01) which was driven almost exclusively by the
Bantle et al. [16] trial in males and weakened considerably by the
removal of anyone trial. There was no evidence of heterogeneity in
the overweight/obese participants (I2 ¼ 0%, P ¼ 0.67) or partici-
pants with diabetes (I2 ¼ 30%, P ¼ 0.20). The heterogeneity in the
otherwise healthy participants drove signiﬁcant heterogeneity in
the overall analysis (I2 ¼ 61%, P ¼ 0.002) and was again explained
by Bantle et al. [16]. Systematic removal of each individual trial
during sensitivity analyses showed that the removal of Bantle et al.
[16] eliminated the evidence for heterogeneity in the healthy par-
ticipants and the overall analysis.
None of the a priori subgroup analyses were signiﬁcant
(Appendix Fig. 1). Fructose in isocaloric substitution for glucose,
however, did increase postprandial triglycerides, although this ef-
fect was not statistically different from the lack of effect of fructose
on postprandial triglycerides where starch, sucrose, or HFCS were
the comparators (P < 0.10). This effect was again inﬂuenced
considerably by Bantle et al. [16]. Signiﬁcant evidence of unex-
plained heterogeneity remained within most of the analyses.
Meta-regression analyses did not show evidence of a signiﬁcant
association between fructosedose and effect size (P for slope¼ 0.981)
(Appendix Fig. 2).Study Year Participants % Weight
Participants without
Stanhope et al. [25]








Heterogeneity: Tau² = 0.02; Chi² = 1.28, df = 1 (P = 0.26); I² = 22%
Test for overall effect: Z = 3.61 (P = 0.0003)
Fig. 3. Forest plots of controlled feeding trials of the effect of fructose supplementing contro
diets alone on pooled postprandial triglyceride endpoints in diabetic and non-diabetic subje
Inverse Variance random effects models. Inter-study heterogeneity was tested by Cochran’3.4. Hypercaloric feeding trials
Fructose supplementation signiﬁcantly increased postprandial
triglycerides (SMD¼ 0.65 [95% CI: 0.30e1.01]) in hypercaloric trials
(Fig. 3), with no evidence of interstudy heterogeneity. Neither
sensitivity nor subgroup analyses were performed owing to the
small number of trials.
3.5. Publication bias
Funnel plots were inspected for the presence of publication bias
in isocaloric trials (Appendix Fig. 3). There was a suggestion of
funnel plot asymmetry where a small number of trials favoring a
postprandial decreasing effect of fructose. However, neither Egger
nor Begg tests provided sufﬁcient evidence of publication bias for
postprandial triglycerides (Egger test, P ¼ 0.514; Begg test,
P ¼ 0.870). Too few trials were available for a meaningful assess-
ment of publication bias in the hypercaloric trials.
4. Discussion
This systematic review and meta-analysis of 14 controlled
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in isocaloric substitution for other carbohydrate, fructose does not
raise postprandial triglycerides. However, in hypercaloric trials, in
which fructose supplements the background diet with excess en-
ergy (þ25% energy) at high doses (wþ175-g/day) compared with
the background diet alone, fructose does show a signiﬁcant post-
prandial triglyceride raising effect. The increase in postprandial
triglycerides was 0.81 mmol/L.
The lack of an overall effect of fructose on postprandial tri-
glycerides in the isocaloric trials was unexpected. Fructose is thought
to mediate increases in triglyceride by acting as an unregulated
substrate for hepatic de novo lipogenesis. It has also been shown to
upregulate fatty acid synthase levels, independent of insulin, leading
to increases in triglyceride secretion and impaired lipoprotein lipase
activity leading to a decreased triglyceride clearance in animal
models [27]. Acute, single-bolus feeding studies have supported
these mechanisms, demonstrating that fructose leads to greater
triglyceride and VLDL levels compared to equal amounts of glucose
in healthy, normal weight [28] and obese [29] participants. The
reasons for why similar effects were not seen in the present analyses
of longer-term trials may relate to dose. The animal models provide
fructose at 60% energy [30] and the two acute, single-bolus feeding
studies which have found an effect tested intakes of fructose 30e40%
energy. A third acute, single-bolus feeding study of fructose
compared with glucose at a lower level of intake (25% energy) did
not show a signiﬁcant increase in postprandial triglycerides [31]. In
the present analyses, the available isocaloric trials which failed to
show an effect of fructose tested median intakes at 20% energy. A
postprandial triglyceride-raising effect was seen only in the hyper-
caloric trials where fructose provided 25% excess energy relative to
the background diet alone. These same trials, however, used excess
energy diets (positive energy balance) in both the fructose arm and
another comparator arm with glucose, so permitting the effect of
fructose to be isolated from that of energy under matched yet excess
energy feeding conditions [25,29]. Neither of these trials alone or
when pooled showed an effect of fructose on postprandial tri-
glycerides in these comparisons. In the absence of an effect in
isocaloric comparisons, energy appears to be the dominant driver of
the effect of fructose on postprandial triglycerides in the hypercaloric
comparisons.
We performed categorical subgroup analyses and continuous
meta-regression analyses to assess the robustness of the relation-
ship between fructose and postprandial triglycerides. Previous
meta-analyses identiﬁed a dose-threshold for a triglyceride-raising
effect of fructose: 50-g/d for postprandial and 100-g/d for
fasting triglycerides across different participant groups [8] and
>60-g/d for fasting triglycerides in type 2 diabetes [7]. We could
not reproduce these thresholds. No dose response was seen in
either our categorical or our continuous analyses over the dose
range studied (22.5e182-g/day or 4.5e25% energy). Subgroup ef-
fects have also been shown for other related endpoints in our
earlier systematic reviews and meta-analyses. We showed that
comparator (starch) and follow-up (4-weeks) modiﬁed the effect
of fructose on triglycerides in type 2 diabetes [7], while metabolic
status (overweight/obesity) and fructose form (fruit) modiﬁed the
effect of fructose on body weight. On the other hand, we did not
report any signiﬁcant subgroup effects for blood pressure [32], uric
acid [33] or glycemic control [34]. In the present set of analyses,
none of these subgroup analyses were signiﬁcant, although effect
modiﬁcation could not be ruled out in all cases. Participants who
were overweight/obese showed a postprandial triglyceride raising-
effect and those who were otherwise healthy showed a tendency
for a postprandial triglyceride raising effect. A postprandial tri-
glyceride raising-effect was also observed where fructose was
provided in isocaloric substitution for glucose. These subgroupeffects, however, should be interpreted with caution. The effect in
overweight/obese participants would not have been expected to
differ from the non-signiﬁcant effect in people with diabetes, most
of whom shared an overweight/obese phenotype. The data in
otherwise healthy participants or where glucose was the compar-
ator were inﬂuenced considerably by a single trial [16]. Finally,
formal tests of interaction showed that the effect of fructose where
glucose was the comparator did not differ from the lack of effect of
fructose on postprandial triglycerides where starch, sucrose, or
HFCS were the comparator.
Several limitations exist within the analyses. First are the
inconsistent results between similarly designed trials. A group from
the University of Minnesota [16,17,23] and another group from the
University of Californian at Davis [19,21] each conducted three
trials. These trials had many similar procedures and reporting.
However, they did not have consistent postprandial triglyceride
effects. The widely varying results contribute to the considerable
heterogeneity in the overall and subgroup analysis. Sensitivity an-
alyses demonstrated the heterogeneity in the data can be attributed
to 1 of the trials from the University of Minnesota inmales [16]. This
calls for further trials with longer follow up and more varied fruc-
to`se form and intake levels. Second,much of the data presented are
end-difference values. The majority of trials only reported end
values so a comprehensive review of change from baseline effect
could not be reported. This results in the inability to determine the
effects of baseline triglyceride differences between treatment
groups caused by randomization variation. However, in subgroup
analyses of randomized and non-randomized trials, no differences
were observed. Third, there were only 1 trial with follow up >10
weeks. Longer term trials would be effective in providing evidence
of persistent effects of fructose intake. However, subgroup analyses
of trials with follow up >4-wks show no signiﬁcant overall effects.
Fourth, peak postprandial triglycerides for three trials were
extracted from day-long metabolic proﬁles [16,21]. However, the
peak postprandial triglyceride values from these proﬁles were
found between 4 and 6 h post meal, which is consistent with pre-
vious reports. Finally, only two trials administered fructose below
the CDA recommended limit of 60 g/day [15]. The average dose,
101.1 g/day, exceeds the 95th percentile (87 g/d) of fructose intake
in the U.S. [9]. Subgroup analysis of trials with doses>60 g/d did not
show overall differences between although this demonstrates a
need of further trials at more physiological fructose doses.
In conclusion, our systematic review and meta-analysis dem-
onstrates that fructose in isocaloric exchange for other carbohy-
drate does not raise postprandial triglycerides. A small effect,
however, cannot be ruled out under all isocaloric conditions. As
there may be a postprandial triglyceride raising effect of fructose in
overweight/obese participants and the direction of the pooled ef-
fect estimate favors a triglyceride-raising effect of fructose with the
lower bound of the 95% CI lying very close to unity in otherwise
healthy participants, it is possible that the overall meta-analysis
may become signiﬁcant with the addition of new trials conducted
in these groups. Interpretation of these data, however, remains
complicated by several factors including the large inﬂuence of a
single trial [16]. In contrast, there is a consistent and substantial
postprandial triglyceride-raising effect of fructose seen in hyper-
caloric trials, in which fructose supplements background diets with
excess energy at extreme doses. In the absence of a clear effect in
the isocaloric trials, this postprandial triglyceride-raising effect
seems more attributable to excess energy than fructose. The small
number and size of the available trials, as well as the methodo-
logical limitations and heterogeneity driven by a single trial calls for
further, larger longer, and higher quality fructose feeding trials at
real world doses to assess the effects of fructose on postprandial
triglycerides.
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